Deucravacitinib Rosacea

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Papulopustular Rosacea
Interventions
DRUG

Deucravacitinib

Deucravacitinib 6 mg orally once daily.

DRUG

Placebo

Matching placebo orally once daily.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER